Noile-Immune Biotech

News Release

No. 26021
November 18, 2026
Noile-Immune Biotech Inc.
https://www.noile-immune.com/en/

Research Findings of "Swift PRIME CAR-T", Enabling Shortened Manufacturing Time, Presented at the Annual Meeting of the Japanese Society for Immunology

－*New Research Findings supporting the Development of Next-Generation CAR-T Cell Therapies*－

Noile-Immune Biotech Inc. (hereinafter "the Company") hereby announces that research results on "Swift PRIME CAR-T", a proprietary technology that enables the manufacturing of PRIME CAR-T cells in a significantly shorter time compared to conventional methods and is being developed through a joint research collaboration with the Department of Immunology, Yamaguchi University Graduate School of Medicine, were presented in a poster session at the 55th Annual Meeting of the Japanese Society for Immunology, which is being held at Grand Cube Osaka from November 17 to 19, 2026.

Presentation Details

■ Event Name: The 55th Annual Meeting of the Japanese Society for Immunology
■ Official Website: https://www2.aeplan.co.jp/jsi2026/en/
■ Dates: November 17-19, 2026
■ Venue: Grand Cube Osaka (5-3-51 Nakanoshima, Kita-ku, Osaka City, Osaka Prefecture)
■ Presentation Date：November 17, 2026
■ Title：Short-term-manufacturing of IL-7/CCL19-expressing CAR-T cells improve antitumor effects in a glioblastoma model
■ Presenting Author: Jin Shiraishi[1,2], Yukimi Sakoda[1,3], Atomu Suzuki[1], Taichi Shimabukuro[1], Taro Hamasaki[1], Kosuke Jozaki[1], Keishi Adachi[1,3], Yoichi Mizukami[4], Tomoharu Yoshizumi[2] and Koji Tamada[1,3].

1. Department of Immunology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
2. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
3. Division of Advanced Cell Therapy, Research Institute for Cell Design Medical Science, Yamaguchi University, Ube, Japan.
4. Institute of Gene Research, Yamaguchi University Science Research Center, Ube, Japan.

■ Abstract:

CAR-T cell therapy has demonstrated remarkable therapeutic efficacy against hematologic malignancies; however, its effectiveness against solid tumors, including glioblastoma, remains limited. In this study, we evaluated the efficacy of "Swift 7×19 CAR-T", which utilizes a technology that enables short-term manufacturing of CAR-T cells co-expressing IL-7 and CCL19, against glioblastoma. Swift 7×19 CAR-T cells retained stem cell-like properties and exhibited sustained antitumor activity. Furthermore, in an orthotopic mouse model of glioblastoma, Swift 7×19 CAR-T cells demonstrated potent tumor growth inhibition and prolonged mouse survival. These findings suggest that Swift 7×19 CAR-T cell therapy may represent a promising novel therapeutic strategy for glioblastoma.

Noile-Immune Biotech

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech Inc.

pr@noile-immune.com